Guard Therapeutics International AB (publ)
SSE:GUARD.ST
19.8 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Guard Therapeutics International AB (publ) |
Symbool | GUARD.ST |
Munteenheid | SEK |
Prijs | 19.8 |
Beurswaarde | 199,219,680 |
Dividendpercentage | 0% |
52-weken bereik | 5.1 - 62.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Tobias Larsson Agervald |
Website | https://guardtherapeutics.com |
An error occurred while fetching data.
Over Guard Therapeutics International AB (publ)
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)